Loading
A phase 1/2 trial of bevacizumab, olaparib, iparomlimab and tuvonralimab, QL2107 and other drugs in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.
QLS5132 Combination Therapy in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07453394 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 626 participants, started 2026-04 and due to reach its primary completion in 2027-04. Interventions recorded: QLS5132; Bevacizumab; QLS5132; Platinum; Bevacizumab; QLS5132; Olaparib; Bevacizumab; QLS5132; QL1706; QL2107; QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin. Conditions listed: Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC); Endometrial Cancer; Advanced Solid Tumors; Ovarian Cancer. Primary outcome: Incidence and severity of adverse events; Maximum tolerated dose (MTD); Recommended Phase 2 Dose (RP2D). No results are recorded here; the registry entry is the source.
Shares QL2107, Qilu Pharmaceutical, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares QL2107, Qilu Pharmaceutical, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.